DADUN
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
Generation of four Isl1 reporter iPSC lines from cardiac and tail-tip fibroblasts derived from Ai6IslCre mouse
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocytedeficient mice reconstituted with human NK cells
Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen
Genetic basis for clinical response to CTLA-4 blockade
Routing cancer immunology and immunotherapy from the lab to the clinic 4-5 th March 2014, Center for Applied Medical Research and University Clinic, Pamplona, Spain
Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12
